Tuberc Respir Dis.  1997 Jun;44(3):525-533.

Enhancement of Cytotoxicity by the Combination of Anticancer Drugs in Human Lung Adenocarcinoma Cell Line (PC-14)

Abstract

BACKGROUND
No ideal combination chemotherapy for lung cancer has been established even though lots of combination anticancer chemotherapies have been tried. For the combination of anticancer drugs, the interaction of anticancer drugs is very important but unpredictable factor. In this experiments we designed and tested new experiment to measure the interaction of two anticancer drugs using MTT assay in an attempt to predict clinical response of the combination regimen.
METHODS
With human lung adenocarcinoma cell line (PC-14), the cytotoxic effect of cisplatin adriamycin mitomycin C and etoposide were measured by in Vitro chemosensitivity test (MTT assay). The combined cytotexic effects of combination of two drugs were also measured in every combination of the drug concentrations and analyzed the interaction by Anova analysis of two way factorial design.
RESULTS
Four individual drugs showed cytotoxic effects on PC-14 by dose dependent fashion Comparison of two drug combinations revealed that mitomycin C + cisplatin and adriamycin + cisplatin combinations showed stronger synergistic cytotoxic effects.
CONCLUSION
From this experiments we suggest two combinations of mitomycin C + cisplatin and adriamycin + cisplatin as chemotherapeutic regimens for unresectable non-small cell lung cancer. Furthermore, this experimental deign could be applied b other types of cancer requiring combination anticancer chemotherapy.

Keyword

Lung cancer; Combination chemotherapy; MTT assay; Cytotoxicity

MeSH Terms

Adenocarcinoma*
Carcinoma, Non-Small-Cell Lung
Cell Line*
Cisplatin
Doxorubicin
Drug Combinations
Drug Therapy
Drug Therapy, Combination
Etoposide
Humans*
Lung Neoplasms
Lung*
Mitomycin
Cisplatin
Doxorubicin
Drug Combinations
Etoposide
Mitomycin
Full Text Links
  • TRD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr